<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cenegermin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cenegermin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cenegermin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="118874" href="/d/html/118874.html" rel="external">see "Cenegermin: Drug information"</a> and <a class="drug drug_patient" data-topicid="118875" href="/d/html/118875.html" rel="external">see "Cenegermin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52153103"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Oxervate</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56774954"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Oxervate</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F52114246"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Recombinant Human Nerve Growth Factor</span></li></ul></div>
<div class="block dop drugH1Div" id="F52114420"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97c8554a-af5e-439a-88a3-3be7414b772b">Neurotrophic keratitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Neurotrophic keratitis:</b> Children ≥2 years and Adolescents: Instill 1 drop into the affected eye(s) every 2 hours for 6 doses daily for 8 weeks</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52114260"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F52114261"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F52114419"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="118874" href="/d/html/118874.html" rel="external">see "Cenegermin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97c8554a-af5e-439a-88a3-3be7414b772b">Neurotrophic keratitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurotrophic keratitis:</b> Instill 1 drop into affected eye(s) 6 times daily at 2-hour intervals for 8 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed, continue treatment at the next scheduled administration.</p></div>
<div class="block dora drugH1Div" id="F52114422"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F52114423"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F51820734"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Eye pain (16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal deposits, foreign body sensation of eye, lacrimation, ocular hyperemia, ophthalmic inflammation, photophobia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Ophthalmic: Blepharitis (including crusting of eyelid [margin], eyelid edema), corneal disease (corneal neovascularization), eye irritation</p></div>
<div class="block coi drugH1Div" id="F51804296"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F52114414"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: May cause mild to moderate eye discomfort (eg, eye pain); notify health care professional if more serious eye reactions occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Remove contact lenses prior to administration and wait 15 minutes before reinserting.</p></div>
<div class="block foc drugH1Div" id="F52153104"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxervate: Cenegermin-bkbj 0.002% (1 mL)</p></div>
<div class="block geq drugH1Div" id="F52153102"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52184942"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Oxervate Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.002% (per mL): $2,273.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56774955"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxervate: Cenegermin-bkbj 0.002% (1 mL)</p></div>
<div class="block admp drugH1Div" id="F52614685"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: Prior to dispensing, weekly carton is kept frozen. If treatment is initiated immediately after receiving the weekly carton, vials may still be frozen and first vial must be thawed (may take up to 30 minutes at room temperature). Attach vial adapter to vial. Clean surface of valve on the connector part of the vial adapter; wait ~1 minute and screw pipette (clockwise) into the connector part of the vial adapter; make sure plunger is pushed all the way down. Invert vial and gently pull pipette plunger until it stops (to draw the eye drop solution into the pipette). After the pipette has been correctly filled, unscrew pipette (counter-clockwise) from the connector part of the vial adapter.</p>
<p style="text-indent:-2em;margin-left:2em;">Wash hands before use; pull down lower eyelid and administer into the conjunctival fornix (space between inner eyelid and eyeball). Blink a few times so the surface of the eye is covered. Discard pipette immediately after use. If using drops in both eyes, use new pipette for each eye. See manufacturer's labeling for detailed administration. Remove contact lenses prior to instillation and wait at least 15 minutes before reinserting. If more than one topical ophthalmic medication is being used, separate administration of other ophthalmic products by at least 15 minutes to avoid dilution of products; administer cenegermin at least 15 minutes prior to eye ointment, gel, or other viscous eye drops. If a dose is missed, continue treatment at the next scheduled administration.</p></div>
<div class="block adm drugH1Div" id="F52114425"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Ophthalmic: If more than one topical ophthalmic drug is being used, administer the drugs at least 15 minutes apart; administer cenegermin 15 minutes prior to any eye ointment, gel, or other viscous eye drops. Remove contact lenses prior to administration and wait 15 minutes before reinserting. Pull down lower eyelid and administer into the conjunctival fornix (space between inner eyelid and eyeball). Keep head tilted back and blink a few times so the surface of the eye is covered. Discard pipette immediately after use and use a new pipette for each eye and administration. See manufacturer's labeling for detailed administration.</p></div>
<div class="block sts drugH1Div" id="F52114416"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at -20°C (-4°F). Dispense weekly carton in the insulated pack in the Delivery System Kit. Within 5 hours of leaving the pharmacy, store the weekly carton at 2°C to 8°C (36°F to 46°F) for up to 14 days. Opened vials, including those with the vial adapter connected, may be stored in the original weekly carton in the refrigerator between 2°C to 8°C (36°F to 46°F) or at room temperature up to 25°C (77°F) for up to 12 hours. Do not refreeze; do not shake vial. Discard any unused portion.</p></div>
<div class="block usep drugH1Div" id="F53571495"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of neurotrophic keratitis (FDA approved in ages ≥2 years and adults)</p></div>
<div class="block cyt drugH1Div" id="F51821975"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F51821972"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F52114412"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block pha drugH1Div" id="F52114418"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (ie, TrkA) and low-affinity (ie, p75NTR) nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F51843591"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Oxervate</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Oxervate</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Oxervate</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Oxervate</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Oxervate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Oxervate (cenegermin-bkbj) [prescribing information]. Boston, MA: Dompé US Inc; October 2019.</div>
</li>
<li>
<div class="reference">
                  Oxervate (cenegermin-bkbj) [prescribing information]. Boston, MA: Dompé US Inc; October 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 119701 Version 42.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
